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AbstrAct
Introduction Gestational diabetes mellitus (GDM) is a 
state of glucose intolerance with onset during pregnancy. 
GDM carries prenatal and perinatal risks as well as 
long-term risks for the mother and her child. GDM may 
be involved in the foetal programming of long-term 
cardiovascular health. However, evidence is sparse and 
the effect of GDM on cardiovascular health is unknown. 
To address these issues, we will conduct MySweetHeart 
Cohort study. The objectives are to assess the effect of 
GDM on offspring’s cardiovascular health early in life by 
using surrogate markers of cardiovascular disease and 
atherosclerosis.
Methods and analysis This is a cohort study of 100 
offspring of women with GDM and 100 offspring of women 
without GDM. At inclusion, a baseline assessment of the 
mothers will be conducted through means of self-report 
questionnaires, a researcher-administrated interview, 
blood pressure and anthropometric measurements, and 
a maternal blood sampling. Between the 30th and 34th 
weeks of gestation, a foetal echography will be performed 
to assess the foetal cardiac structure and function, the 
fetomaternal circulation and the hepatic volume. At birth, 
maternal and neonatal characteristics will be assessed. 
An echocardiography will be performed to assess cardiac 
structure and function 2–7 days after birth; carotid intima-
media thickness will be also measured to assess vascular 
structure. MySweetHeart Cohort is linked to MySweetHeart 
Trial ( clinicaltrials. gov/ ct2/ show/ NCT02890693), a 
randomised controlled trial assessing the effect of 
a multidimensional interdisciplinary lifestyle and 
psychosocial intervention to improve the cardiometabolic 
and mental health of women with GDM and their offspring. 
A long-term follow-up of children is planned.
Ethics and dissemination Ethical approval has been 
obtained through the state Human Research Ethics 
Committee of the Canton de Vaud (study number 
2016–00745). We aim to disseminate the findings through 
regional, national and international conferences and 
through peer-reviewed journals.
trial registration number  ClinicalTrials. gov ( clinicaltrials. 
gov/ ct2/ show/ NCT02872974).
IntroductIon
Maternal hyperglycaemic disorders during 
pregnancy
The prevalence of maternal hyperglycaemic 
disorders during pregnancy is increasing in 
the population due to the obesity epidemic 
and the increasing age of pregnant mothers.1–3 
Maternal hyperglycaemic disorders include 
type 1 and 2 diabetes mellitus (T1/T2DM) 
and gestational diabetes mellitus (GDM). T1/
T2DM is a state of glucose intolerance occur-
ring independently of pregnancy, while GDM 
is characterised by glucose intolerance that 
begins or is first diagnosed during pregnancy 
and usually resolves after delivery.4 5 GDM is 
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Protocol
strengths and limitations of this study
 ► This study will increase our understanding of 
the impact of gestational diabetes mellitus on 
cardiometabolic health during foetal and neonatal 
periods. Within a Developmental Origin of Health and 
Disease framework, it will contribute to improving 
the knowledge on the early life conditioning 
(programming) mechanisms and their influence on 
infants’ cardiovascular health.
 ► A major strength of our study is the assessment at 
birth of surrogate markers of cardiovascular disease 
(CVD)  (left ventricular mass index and subclinical 
atherosclerosis (carotid intima- media thickness)).
 ► Acknowledged limitations are the relatively small 
sample size, the potential for residual confounding 
and the limited representativeness of our sample 
(monocentric study).
 ► A better understanding of the clinical impact of the 
maternal hyperglycaemic disorders on offspring’s 
health early in life is needed to inform strategies for 
the early prevention of CVD.
 ► A long-term follow-up of children is planned for 
further assessment of their cardiovascular health.
group.bmj.com on November 23, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Di Bernardo S, et al. BMJ Open 2017;0:e016972. doi:10.1136/bmjopen-2017-016972
Open Access 
associated with an increased risk of maternal metabolic 
syndrome and T2DM2 3 6 and is now the most frequent 
form of hyperglycaemic disorders during pregnancy.2
Maternal T1/T2DM diabetes is associated with signif-
icant fetal and neonatal morbidity,4 for example, large 
for gestational age (LGA), congenital malformations and 
neonatal metabolic disorder (hypoglycaemia).3 7 8 There 
is some evidence that the foetal consequences are more 
serious with T1/T2DM diabetes than with GDM4 and, 
until recently, the consequences of GDM on offspring’s 
health were uncertain.9 Nevertheless, the large high-sensi-
tiviy C reactive protein (HAPO) cohort study showed that 
maternal hyperglycaemia less severe than in T1/T2DM, 
after correction for potential confounders (maternal 
obesity, blood pressure), was also associated with adverse 
perinatal outcomes, that is, LGA, neonatal hyperin-
sulinism and hypoglycaemia, and pre-eclampsia.9–11 
Furthermore, in large randomised trials, treatment of 
GDM resulted in better perinatal outcomes, including a 
reduced risk of LGA.4 12–15
Following the results of these studies, the Interna-
tional Association of Diabetes and Pregnancy Study 
Groups (IADPSG) have proposed new criteria to diag-
nose GDM.3 The benefits of screening and treatment of 
GDM have long been debated14–17 and recommendations 
from medical societies varied from no screening at all, 
screening only high-risk women (risk-based screening), 
to universal screening. Thus, the IADPSG recommend 
universal one-stage screening procedure that includes a 
2-hour 75 g oral glucose tolerance test (OGTT). A single 
abnormal glucose concentration at fasting, at 1 hour or 
at 2 hours is sufficient for the diagnosis of GDM.14 New 
blood glucose threshold were derived from the HAPO 
study and based on pregnancy outcomes associated with 
the glucose level.10 14 Using these criteria, the prevalence 
of GDM is expected to be high, reaching up to 10%–20% 
of pregnant women in US populations.3
cArdIoMEtAbolIc EffEcts of MAtErnAl dM
Maternal hyperglycaemic disorders are associated with 
fetal cardiac and vascular structural and functional alter-
ations. For instance, it is well known that offspring of 
T1/T2DM mothers are at increased risk of congenital 
cardiac malformations and cardiac hypertrophy.8 18 In a 
retrospective study of 92 offspring of 87 diabetic mothers 
conducted in Lausanne, we observed that 5 neonates had 
congenital heart disease and 12 had ventricular hyper-
trophy.8 There is also growing evidence that maternal 
hyperglycaemic disorders may be involved in the ‘foetal 
programming’ of obesity and metabolic disorders in their 
offspring.11 19 Within a Developmental Origin of Health 
and Disease (DOHaD) framework,20 21 fetal programming 
(or conditioning) is the process involved in the associa-
tions between the exposure to detrimental factors during 
foetal life and health outcomes later in life.22 Foetal 
programming is suspected to be involved in the devel-
opment of cardiometabolic disorders, such as elevated 
blood pressure, coronary heart diseases or DM, notably 
through epigenetic mechanisms.20 21 Despite recent and 
large growth in this research area, studies are needed to 
better objectively characterise both early life exposures 
and cardiometabolic outcomes.23
Intrauterine exposure to high maternal blood glucose 
is associated with foetal hyperinsulinism which is respon-
sible for structural and functional changes affecting 
mostly the liver and the cardiovascular system. The liver 
is the major metabolic organ, considered as the meta-
bolic brain and responsible for the distribution of the 
placental resources.24 Recent studies have shown that 
macrosomic offspring had impaired liver blood perfusion 
that contributes to foetal growth alteration25–27 and that 
differential perfusion of the foetal liver modified hepatic 
metabolic function and size.24 Studies indicate that the 
liver is enlarged in foetuses of T1/T2 DM mothers.28 29 
Furthermore, and similarly the foetal heart response to 
hyperinsulinism is the development of an asymmetrical 
hypertrophy predominant at the septal wall. The evalu-
ation of liver volume, interventricular septum thickness 
and left ventricular mass is therefore of outmost impor-
tance and may represent surrogate markers of the foetal 
metabolic response to maternal GDM.
lAck of dAtA on thE EffEcts of GdM on offsprInG’s 
cArdIovAsculAr hEAlth
Most studies on the effect of maternal hyperglycaemic 
disorders were conducted among mothers with T1/
T2DM, not among mothers with GDM and with an 
emphasis on the effects on offspring’s metabolic 
outcomes rather than on offspring’s cardiovascular 
health. It is also unknown whether treatment of GDM is 
effective to reduce long-term risk of offspring’s metabolic 
and cardiovascular disease (CVD) risk9 11 15 and the new 
definition of GDM calls also for the conduction of further 
studies on the impact of GDM on offspring’s cardiovas-
cular health. To study the early development of athero-
sclerosis and pathogenesis of CVD, it has become central 
to assess surrogate markers of CVD such as increased 
cardiac mass (left ventricular mass index; LVMI)30 and 
of subclinical atherosclerosis (assessed through carotid 
intima-media thickness; cIMT).30 31 These markers have 
been used extensively in studies in children and young 
adults with CVD risk factors.30–34 However, to our knowl-
edge, the effects of GDM on offspring’s foetal and early 
neonatal cardiovascular health, and in particular on such 
surrogate markers,31 have never been studied.
objEctIvEs
Our objectives are to assess the effect of GDM on 
offspring’s cardiovascular health early in life, namely on 
(1) the surrogate markers of CVD and atherosclerosis at 
birth (LVMI and cIMT) (primary outcomes) and (2) the 
cardiovascular structure and function during the foetal 
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period and potential neonatal cardiovascular risk factors 
(secondary outcomes).
MEthods And AnAlysIs
study design
We plan to conduct a cohort study of 200 offspring of 
women aged 18 years old or more. We will include 100 
women with GDM and 100 without GDM. All pregnant 
women attending the antenatal care clinic or the GDM 
clinic at the Lausanne University Hospital (CHUV) will 
be invited to participate. In addition, women with GDM 
who are followed up by private diabetologists and gynae-
cologists in the Canton de Vaud will be invited to partici-
pate following a similar procedure. Using the new criteria 
of the IADPSG, the expected prevalence of GDM in this 
population is at least ~10%.3 Women with T1/T2D will 
not be included.
study populAtIon
Inclusion criteria: Pregnant women aged 18 years or 
older, with or without GDM at 24–32 weeks of gestation, 
and understanding French or English. Exclusion criteria: 
Women on strict bed rest, with pre-existing DM or severe 
mental disorders precluding participation.
study outcoMEs
Primary outcomes are surrogate markers of CVD 
and atherosclerosis at birth, that is, LVMI and cIMT. 
Secondary outcomes are foetal cardiovascular struc-
ture and function (notably LVMI and liver volume) and 
potential neonatal cardiovascular risk factors (including 
cord blood lipid levels, glycaemia, insulin, high-sensitiviy 
C reactive protein (hs-CRP), etc).
dAtA collEctIon And vIsIts
During pregnancy, in the pre-recruitment phase, all 
pregnant women without pre-existing DM, attending 
the CHUV antenatal care clinic, have a fasting blood 
glucose measurement between the 24th and 28th weeks 
of gestation. GDM is diagnosed if fasting blood glucose 
is equal to or above 5.1 mmol/L. If fasting blood glucose 
is equal to or above 4.4 and below 5.1 mmol/L, preg-
nant women have a 2-hour 75 g OGTT and GDM will be 
diagnosed based on the new criteria of the IADPSG.3 9 
Women screened by private obstetricians in the Canton 
de Vaud undergo either the same procedure or directly a 
2-hour 75 g OGTT. Considering the variability in patients' 
compliance and time of enrolment for prenatal care, all 
eligible women, having been screened for GDM before 
32 weeks of gestation, will be invited to participate (see 
inclusion and exclusion criteria in the Study population 
section).
The participation in the study is voluntary and involves 
a sequence of events and measurements as summarised 
in table 1.
At the first study visit (V1), scheduled between the 24th 
and 32nd weeks of gestation, a baseline assessment of the 
mothers will be conducted through means of self-report 
questionnaires and a researcher-administrated inter-
view, weight, height and blood pressure measurements, 
and a maternal blood sampling. This will provide infor-
mation notably on the socioeconomic status, general 
health status, family medical history of CVD or diabetes, 
smoking and drinking habits and several cardiometa-
bolic biomarkers, all of which will be treated as potential 
confounding factors. If available, paternal data on the 
family history of CVD or diabetes will be also collected at 
the first study visit.
At the second visit (V2), between the 30th and 34th 
weeks of gestation, a foetal echography will be performed 
to assess the fetal cardiac structure (including LVMI) and 
function, the fetomaternal circulation, and the hepatic 
volume.
In women with GDM, information about treatment and 
blood glucose measurements will be recorded during the 
whole pregnancy.
At birth (V3), maternal characteristics (including mode 
of delivery, gravidity, parity, etc) and neonatal character-
istics (including gestational age, sex, weight, length, etc) 
will be assessed. A sample of umbilical cord blood will 
be collected to measure various biomarkers, including 
glucose, insulin, total cholesterol, low-density lipoprotein 
(LDL)-cholesterol, high-density lipoprotein (HDL)-cho-
lesterol, triglycerides, uric acid, creatinine, hs-CRP and 
various miRNA.
An echocardiography will be done to assess cardiac 
structure (including LVMI) and function 2–7 days after 
birth (V4). cIMT will be measured to assess vascular 
structure.
MEAsurEMEnts MEthods
Maternal clinical assessment
Maternal body weight and blood pressure (three readings 
at 2-min intervals with a clinically validated35 oscillometric 
sphygmomanometer (OMRON HEM-907)36 37) will be 
measured during pregnancy (V1, V2) and in postpartum 
(V4). Clinical chemistry (including glucose, hemoglo-
binA1c (HbA1c), insulin, total cholesterol, LDL-cho-
lesterol, HDL-cholesterol, triglycerides, uric acid and 
creatinine) will be assessed at the first study visit (V1) 
and blood will be collected for further potential analyses. 
All samples will be managed and stored in a biobank. 
The clinical data assessed as part of the usual care of 
the mother and potentially influencing the outcomes of 
interest will be collected. Also, information on socioeco-
nomic characteristics, general health, family history of 
CVD or diabetes, smoking and drinking habits and so on 
will be gathered using a self-report questionnaire and a 
researcher-administrated interview.
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offspring clinical assessment
The height and weight of the neonate will be measured 
and the growth reference charts of the Swiss Society of 
Paediatrics will be used.38 39 Gestational age will be deter-
mined using either the date of the last menstrual period 
or the first-trimester ultrasound dating. Clinical chemistry 
(including glucose, total cholesterol, LDL-cholesterol, 
HDL-cholesterol, triglycerides, insulin, uric acid, hs-CRP, 
mi-RNA) will be assessed at birth using cord blood. We 
will explore the profile of circulating non-coding RNAs in 
offspring of women with GDM and without GDM to assess 
the involvement of epigenetic mechanisms in cardio-
vascular alterations.40 Blood for future analyses will be 
stored in a biobank. The clinical data assessed as part of 
the usual care of the offspring and potentially influencing 
the outcomes of interest will be collected.
foetal echography
oThis examination will be performed between the 30th 
and 34th weeks of gestation by two experienced ultraso-
nographers (YM, YV), blinded to the maternal glycaemic 
status, using a Voluson E10 (General Electric Medical 
Systems, ZIPF, Australia) equipped with a 2–8 MHz convex 
array sector transducer.41 A systematic echography will be 
conducted to detect structural and functional anomalies 
following international recommendations.42 43 Anthropo-
metric measurements and foetal well-being parameters 
will be measured.44 Observed foetal weight (FW) will be 
calculated using the Hadlock et al’s formula based on 
the head circumference, biparietal diameter, abdom-
inal circumference and femur length.45 The gestational 
age-adjusted expected FW will be calculated46 and the 
discordance with observed FW will be determined as 
(observed FW−expected FW)/expected FW. This discor-
dance will be used to quantify appropriateness of foetal 
growth. Then, a detailed echocardiography of the foetal 
liver, cardiovascular system and of the maternofoetal 
circulation will be conducted including bidimensional 
(2D), M-Mode (M), Doppler (D) and tridimensional 
(3D) imaging of the following structures: cardiac four 
chambers (2D), right ventricular (RV) and left ventric-
ular (LV) short axis (2D, M), tricuspid, pulmonary, mitral 
and aortic valve (2D, D), umbilical vein, ductus venosus, 
patent ductus arteriosus, aortic isthmus, umbilical arteries 
and maternal uterine arteries (2D, D) and liver (2D, 
3D).47–50 This will allow the assessment of the LV posterior 
wall and septal thickness, the LV mass,51 the LV and RV 
systolic and diastolic function, the cardiothoracic ratio, 
the placental and foetal vascular resistances, the cardiac 
output and liver volume. Data will be digitally stored 
to allow off-line analyses. Measures will be expressed as 
Z-scores based on gestational age to allow comparison 
between foetuses.
neonatal cardiac echography
This examination will be performed 2–7 days after birth 
(before the mother and the newborn leave the clinic) by 
two experienced ultrasonographers (NS, SDB) blinded 
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Figure 1 Hypothetical and highly simplified causal relationships between gestational diabetes mellitus (GDM) and 
cardiometabolic disorders. Two pathways can be hypothesised: (1) a direct effect of GDM on offspring’s cardiometabolic 
disorders; (2) an indirect effect through the mediator large for gestational age (LGA). It means that if LGA was prevented, part 
of the effect of GDM on cardiometabolic disorders would be prevented. Several confounding factors (such as maternal obesity, 
weight gain during pregnancy, smoking, socioeconomic status or family history of cardiometabolic diseases) have to be 
accounted.
to the maternal glycaemic status and to the foetal echo-
cardiogram. Echocardiography will be performed on 
a Philips EPIC echocardiogram with a S8-3 or S12 MHz 
transducer, digitally recorded (Xcelera, Philips) and 
analysed off-line. Standard echocardiography including 
2D, M-mode, colour and spectral Doppler according to 
the American Society of Echocardiograph (ASE) will 
be performed.52 53 Measurements will be performed 
according to the standard of the ASE52 53 including: (1) 
right and left atrial chamber sizes; (2) LV size, volume 
and function; (3) LV mass; (4) LV and RV systolic and 
diastolic function. Z-scores based on BSA calculated 
by the Haycock formula will be used to express these 
measurements.54–56
neonatal carotid echography
This examination will be performed 2–7 days after birth 
(before the mother and the newborn leave the clinic) by 
two experimented ultrasonographers (NS, SDB) blinded 
to the maternal glycaemic status. Carotid IMT measure-
ment will be performed on a Philips EPIC echocardio-
graph (Philips Medical, Netherland) with a L 11–5 MHz 
high-resolution linear array transducer, recorded on 
a digital system (QLab, Philips Medical Netherlands). 
Image acquisition will be done according to the standard 
of the American Heart Association Atherosclerosis, Hyper-
tension and Obesity in Youth Committee of the Council 
on CVD in the Young.31 Image analyses will include: (1) 
far-wall cIMT; (2) calculation of the mean of maximal 
cIMT measurements; (3) calculation of carotid stiffness. 
Measurements of cIMT will be expressed in millimetre as 
mean±SD and compared with normal cIMTs.57 58 We have 
recently conducted a study to show that the measurement 
of cIMT was feasible in young non-sedated infants. This 
study conducted among 81 infants less than 1 year of age 
confirmed that cIMT was measurable with a high interob-
server reliability (coefficient of variation: 5.9%).59
AntIcIpAtEd rEcruItMEnt
Recruitment has begun in September 2016. About 3200 
deliveries per year occur at our hospital and about 250 
pregnant women are followed for GDM at our special-
ised clinic. A relatively large share of patients consists of 
immigrants who do not speak English or French and will 
not be eligible for participation. We therefore expect to 
include up to two pregnant women per week, hence to 
include the 200 subjects in 30 months. A research coor-
dinator (SE) and a PhD student (AME) will be respon-
sible to screen all women for eligibility and to ensure 
follow-up throughout the study duration. Recruitment 
will be facilitated by the high support of obstetricians 
at the CHUV. We will also benefit of the new specialised 
GDM clinic of the CHUV where every pregnant woman 
who screened positive for GDM at the CHUV antenatal 
care clinic is followed up. MySweetHeart Cohort is linked 
to MySweetHeart Trial ( clinicaltrials. gov: NCT02890693; 
led by Professor Jardena Puder and PD Dr Antje Horsch), 
a randomised controlled trial led by this new specialised 
GDM clinic designed to assess the effect of a multidi-
mensional interdisciplinary lifestyle and psychosocial 
intervention to improve the cardiometabolic and mental 
health of women with GDM and their offspring. Little loss 
to follow-up is expected because measurements are made 
during pregnancy and shortly after delivery. Neverthe-
less, to minimise loss to follow-up, most appointments are 
made on the days of regular follow-up visits and the post-
natal echocardiography is scheduled before the mother 
and the baby leave the hospital.
sAMplE sIzE
Assuming that LVMI will be 30 g/m2.7(SD: 4.5) in children 
of mothers without GDM60compared with 32 g/m2.7(SD: 
4.5) in children of women with GDM, the required sample 
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size is 80 women with GDM and 80 women without GDM 
to have a statistical significant difference with a power 
of 80% and an alpha-level set at 0.05 (two sided). This 
sample size is also sufficient to observe statistical signifi-
cant differences in cIMT at birth if we assume that cIMT 
at birth is 0.44 mm (SD: 0.04)31 in newborn of women 
with GDM and 0.42 mm (SD: 0.04) in newborn of women 
without GDM. In the worst case scenario, we could lose 
up to 20% of participants between inclusion and delivery. 
Therefore, we plan to include 100 pregnant women with 
GDM and 100 women without GDM.
stAtIstIcAl AnAlysIs
The association between exposure (GDM/no GDM) and 
the (continuous) outcomes will be estimated with linear 
regression analyses. Adjustment for potential confounding 
factors (maternal characteristics such as age, body mass 
index, blood pressure, socioeconomic status, personal 
history of CVD, treatment for GDM during pregnancy) 
will be done. To assess the direct and indirect (through 
mediators) effects of GDM on the outcomes, causal medi-
ation analyses will be conducted.61 62 Because LGA is a 
potential mediator of the effect of GDM on offspring 
outcomes,63 analyses adjusted on birth weight will be 
conducted to estimate the indirect effect of GDM on the 
outcomes (figure 1). We will also consider the effect of 
treatment which will be treated as a mediator between 
GDM, LGA and outcomes.
EthIcs And dIssEMInAtIon
The study poses little to no risk to participants and their 
offspring. Signed informed consent is obtained from all 
participating women. Participation in the study does not 
interfere with the typical care patients receive during 
pregnancy and after delivery. Clinicians in the obstetrical 
clinic provide clinical follow-up and, if necessary, partici-
pants are referred on for additional clinical management.
Results from this study will be disseminated at regional 
and international conferences and in peer-reviewed 
journals.
sIGnIfIcAncE And outlook
The current high prevalence of maternal obesity and 
associated hyperglycaemic disorders may lead to a perpet-
uating intergenerational cycle of increasing obesity, 
metabolic and cardiovascular disorders. Well-designed 
prospective studies are necessary to better quantify the 
actual impact of maternal hyperglycaemic disorders on 
offspring’s health and to identify the potential under-
lying mechanisms. Despite recent significant advances in 
DOHaD and foetal programming research, major chal-
lenges have to be addressed, notably by better objectively 
characterising both early life exposure and cardiometa-
bolic outcomes.23
Indeed, many past studies on the foetal programming 
of cardiometabolic disorders suffered from some meth-
odological flaws including confounding, no or poor stan-
dardisation of exposure and outcome assessment, and 
selection bias. Our prospective population-based study 
in pregnant women whose offspring is examined during 
fetal life and at birth avoids some of these issues. The 
long period needed for CVD to develop could be a limita-
tion, but this will be overcome in our study by measuring 
surrogate outcomes (including LVMI and cIMT) that are 
well-established precursors of CVD.31 In addition, a long-
term follow-up of the offspring is planned (not funded 
yet) for further assessment of their cardiovascular health.
By looking at the fetomaternal circulation, foetal 
cardiovascular system and liver and foetal growth and 
CVD risk markers at birth, we will acquire unique data 
to gain insight in the early mechanisms underlying the 
development of CVD and metabolic diseases and on the 
role of maternal hyperglycaemic disorders. GDM is an 
opportunity for timely intervention for the prevention of 
cardiometabolic disorders in mothers and their offspring.9 
With the new criteria to define GDM, a growing propor-
tion of women will be concerned by this disorder. Having 
a better understanding of the clinical impact of maternal 
hyperglycaemic disorders on offspring’s health early in 
life is urgently needed to inform strategies for the early 
prevention of CVD.
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